Arvinas Inc (ARVN)

$25.01

+0.01

(+0.04%)▲

Market is closed - opens 7 PM, 11 Oct 2024

Performance

  • $24.26
    $25.01
    $25.01
    downward going graph

    3.0%

    Downside

    Day's Volatility :3.0%

    Upside

    0.0%

    downward going graph
  • $13.57
    $53.08
    $25.01
    downward going graph

    45.74%

    Downside

    52 Weeks Volatility :74.43%

    Upside

    52.88%

    downward going graph

Returns

PeriodArvinas IncSector (Health Care)Index (Russel 2000)
3 Months
-12.61%
3.7%
0.0%
6 Months
-32.88%
8.3%
0.0%
1 Year
29.45%
17.1%
0.0%
3 Years
-69.39%
21.3%
-20.3%

Highlights

Market Capitalization
1.7B
Book Value
$8.75
Earnings Per Share (EPS)
-5.3
Wall Street Target Price
65.78
Profit Margin
0.0%
Operating Margin TTM
-63.4%
Return On Assets TTM
-19.63%
Return On Equity TTM
-60.8%
Revenue TTM
93.3M
Revenue Per Share TTM
1.44
Quarterly Revenue Growth YOY
40.400000000000006%
Gross Profit TTM
131.4M
EBITDA
-366.2M
Diluted Eps TTM
-5.3
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.51
EPS Estimate Next Year
-4.63
EPS Estimate Current Quarter
-0.86
EPS Estimate Next Quarter
-1.07

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 26 Wall street analysts offering stock ratings for Arvinas Inc(by analysts ranked 0 to 5 stars)
Based on 26 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
23
23
24
Hold
3
3
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 163.01%

Current $25.01
Target $65.78

Company Financials

FY18Y/Y Change
Revenue
14.3M
↑ 89.0%
Net Income
-41.5M
↑ 72.48%
Net Profit Margin
-289.59%
↑ 27.73%
FY19Y/Y Change
Revenue
43.0M
↑ 200.03%
Net Income
-62.1M
↑ 49.79%
Net Profit Margin
-144.57%
↑ 145.02%
FY20Y/Y Change
Revenue
21.8M
↓ 49.27%
Net Income
-111.8M
↑ 79.92%
Net Profit Margin
-512.74%
↓ 368.17%
FY21Y/Y Change
Revenue
46.7M
↑ 114.2%
Net Income
-183.2M
↑ 63.88%
Net Profit Margin
-392.29%
↑ 120.45%
FY22Y/Y Change
Revenue
131.4M
↑ 181.37%
Net Income
-271.9M
↑ 48.42%
Net Profit Margin
-206.93%
↑ 185.36%
FY23Y/Y Change
Revenue
78.5M
↓ 40.26%
Net Income
-367.3M
↑ 35.09%
Net Profit Margin
-467.9%
↓ 260.97%
Q1 FY23Q/Q Change
Revenue
32.5M
↓ 14.47%
Net Income
-80.8M
↑ 1.13%
Net Profit Margin
-248.62%
↓ 38.36%
Q2 FY23Q/Q Change
Revenue
54.5M
↑ 67.69%
Net Income
-66.6M
↓ 17.57%
Net Profit Margin
-122.2%
↑ 126.42%
Q3 FY23Q/Q Change
Revenue
34.6M
↓ 36.51%
Net Income
-64.0M
↓ 3.9%
Net Profit Margin
-184.97%
↓ 62.77%
Q4 FY23Q/Q Change
Revenue
-43.1M
↓ 224.57%
Net Income
-154.8M
↑ 141.88%
Net Profit Margin
359.16%
↑ 544.13%
Q1 FY24Q/Q Change
Revenue
25.3M
↓ 158.7%
Net Income
-69.4M
↓ 55.17%
Net Profit Margin
-274.31%
↓ 633.47%
Q2 FY24Q/Q Change
Revenue
76.5M
↑ 202.37%
Net Income
-35.2M
↓ 49.28%
Net Profit Margin
-46.01%
↑ 228.3%
FY18Y/Y Change
Total Assets
199.3M
↑ 198.11%
Total Liabilities
62.6M
↓ 5.99%
FY19Y/Y Change
Total Assets
301.6M
↑ 51.36%
Total Liabilities
75.0M
↑ 19.71%
FY20Y/Y Change
Total Assets
717.4M
↑ 137.82%
Total Liabilities
75.1M
↑ 0.21%
FY21Y/Y Change
Total Assets
1.6B
↑ 120.47%
Total Liabilities
799.9M
↑ 964.96%
FY22Y/Y Change
Total Assets
1.3B
↓ 19.78%
Total Liabilities
703.9M
↓ 12.0%
FY23Y/Y Change
Total Assets
1.3B
↑ 2.82%
Total Liabilities
644.6M
↓ 8.42%
Q1 FY23Q/Q Change
Total Assets
1.2B
↓ 7.33%
Total Liabilities
664.8M
↓ 5.55%
Q2 FY23Q/Q Change
Total Assets
1.1B
↓ 7.85%
Total Liabilities
619.9M
↓ 6.75%
Q3 FY23Q/Q Change
Total Assets
1.1B
↓ 2.33%
Total Liabilities
601.1M
↓ 3.03%
Q4 FY23Q/Q Change
Total Assets
1.3B
↑ 23.27%
Total Liabilities
644.6M
↑ 7.24%
Q1 FY24Q/Q Change
Total Assets
1.2B
↓ 7.05%
Total Liabilities
602.9M
↓ 6.47%
Q2 FY24Q/Q Change
Total Assets
1.3B
↑ 5.53%
Total Liabilities
679.4M
↑ 12.69%
FY18Y/Y Change
Operating Cash Flow
-16.1M
↓ 415.22%
Investing Cash Flow
-179.7M
↓ 960.79%
Financing Cash Flow
168.1M
↓ 104250.7%
FY19Y/Y Change
Operating Cash Flow
-40.6M
↑ 152.06%
Investing Cash Flow
-93.1M
↓ 48.18%
Financing Cash Flow
139.7M
↓ 16.85%
FY20Y/Y Change
Operating Cash Flow
-89.8M
↑ 120.93%
Investing Cash Flow
164.3M
↓ 276.43%
Financing Cash Flow
504.7M
↑ 261.14%
FY21Y/Y Change
Operating Cash Flow
559.4M
↓ 723.24%
Investing Cash Flow
-1.3B
↓ 899.76%
Financing Cash Flow
278.6M
↓ 44.8%
FY22Y/Y Change
Operating Cash Flow
-273.5M
↓ 148.89%
Investing Cash Flow
242.8M
↓ 118.48%
Financing Cash Flow
4.7M
↓ 98.31%
Q1 FY23Q/Q Change
Operating Cash Flow
-91.2M
↑ 28.09%
Investing Cash Flow
138.6M
↑ 614.43%
Financing Cash Flow
1.5M
↑ 200.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-88.7M
↓ 2.74%
Investing Cash Flow
48.6M
↓ 64.94%
Financing Cash Flow
500.0K
↓ 66.67%

Technicals Summary

Sell

Neutral

Buy

Arvinas Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arvinas Inc
Arvinas Inc
0.48%
-32.88%
29.45%
-69.39%
42.18%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-12.48%
8.55%
19.49%
82.88%
232.15%
Novo Nordisk A/s
Novo Nordisk A/s
-13.09%
-6.28%
18.91%
138.88%
358.83%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
6.38%
83.19%
66.02%
36.22%
252.82%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.3%
18.97%
30.36%
165.15%
176.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arvinas Inc
Arvinas Inc
NA
NA
NA
-3.51
-0.61
-0.2
NA
8.75
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.81
26.81
1.38
45.04
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
39.53
39.53
1.79
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.38
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arvinas Inc
Arvinas Inc
Buy
$1.7B
42.18%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.6B
232.15%
26.81
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$519.8B
358.83%
39.53
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$35.8B
252.82%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$122.9B
176.17%
32.84
-4.74%

Insights on Arvinas Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, -43.1M → 76.5M (in $), with an average increase of 168.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -154.8M → -35.2M (in $), with an average increase of 110.1% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.0% return, outperforming this stock by 36.5%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 36.2% return, outperforming this stock by 105.6%

Institutional Holdings

  • EcoR1 Capital, LLC

    9.80%

  • Vanguard Group Inc

    9.72%

  • BlackRock Inc

    9.12%

  • T. Rowe Price Associates, Inc.

    5.81%

  • Avidity Partners Management LP

    4.35%

  • RTW INVESTMENTS, LLC

    4.32%

Company Information

arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.

Organization
Arvinas Inc
Employees
445
CEO
Dr. John G. Houston Ph.D.
Industry
Health Technology

Discover More

FAQs